Quick Facts

• Therapeutic Domain: Respiratory conditions.
• Primary Use: Management of reversible airways obstruction.
• Beneficial for: Individuals with asthma and certain chronic obstructive pulmonary diseases (COPD).

---

Астмопент (orciprenaline) is a medication utilized in therapeutic regimens focused on addressing reversible obstruction within the airways. This condition, which involves difficulty with breathing due to narrowed air passages, is frequently encountered in the context of asthma and other respiratory diseases like chronic obstructive pulmonary disease (COPD). The primary benefit of using Астмопент is its role in supporting the relaxation of muscles surrounding the airways, which helps facilitate improved airflow and respiratory function.

The medication is classified as a bronchodilator, a class of agents intended to assist in managing episodes of breathing difficulty and is used in maintenance therapy. It contributes to the care plan by providing relief from the symptoms associated with airways obstruction. Its clinical use and licensing have been subject to review in light of the availability of newer treatment options.

Who Can and Cannot Use Астмопент?

The eligibility for using Астмопент (Orciprenaline/Metaproterenol) is defined by official regulatory documents based on a patient’s age, pre-existing health conditions, and physiological status. Use is established for individuals with reversible airways obstruction (e.g., asthma, chronic bronchitis) who meet the following criteria.

---

Regulatory Eligibility Classifications

Classification	Population or Condition
Contraindicated (Prohibited Use)	Known hypersensitivity to the drug or any component.
	Patients with cardiac arrhythmias associated with tachycardia (fast heartbeat).
	Patients with hypertrophic obstructive cardiomyopathy (HOCM).
Conditional Use (Use with Caution)	Patients with ischemic heart disease, hypertension, hyperthyroidism, diabetes mellitus, or convulsive disorders (seizures).

Age and Reproductive Status

• Pediatric Use: Oral formulations are not recommended for use in children under 6 years of age because safety and effectiveness have not been formally established.
• Pregnancy & Lactation: Use during pregnancy and breastfeeding is generally restricted, and should only be undertaken if the official benefit is judged to outweigh the potential risk to the fetus or newborn, as documented in prescribing information.

Regulatory criteria mandate that use is strictly confined to these labeled populations and conditions.

Interactions with other medicines and products

The official regulatory profile for Orciprenaline (Metaproterenol) primarily details specific pharmacodynamic interaction patterns with other medicinal products, leading to mandatory co-administration restrictions.

Formal Restrictions and Prohibitions

Classification	Interacting Agent	Official Regulatory Statement
Contraindicated	Beta-Adrenergic Blocking Agents (e.g., Propranolol)	Co-administration is formally prohibited due to the effective antagonism of the bronchodilatory action.
Requires Extreme Care	Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs)	Co-use may potentiate the effect on the vascular system, requiring careful consideration due to enhanced risk.
Not Recommended	Other Sympathomimetic Agents	Concomitant use is discouraged due to the potential for deleterious cardiovascular effects; a sufficient interval should elapse between doses.

Risk of Additive Effects

Co-administration with xanthine derivatives, corticosteroids (steroids), and diuretics may potentiate the official adverse effect of hypokalemia (low serum potassium). Similarly, co-use with Halogenated Hydrocarbon Anesthetics may increase susceptibility to cardiovascular effects. Regulatory guidance derived from official patient information notes that non-prescribed substances, including alcohol, caffeine, and nicotine (from tobacco), can affect the action of many medications.

How Астмопент Works

beta2-Adrenergic Receptor Targeting and cAMP Signaling

This mechanism involves the drug's primary action as a selective agonist at beta2-adrenergic receptors (ARs), which are located on the smooth muscle cells lining the airways. Receptor binding initiates a G-protein signaling cascade, leading to the activation of adenylyl cyclase and an increase in the intracellular concentration of the second messenger cyclic AMP (cAMP).

---

Airway Smooth Muscle Relaxation

The elevated cAMP concentration mediates a core mechanistic cascade by activating protein kinase A (PKA). PKA activity subsequently reduces intracellular calcium availability and modulates the activity of myosin light-chain kinase. This intracellular process directly inhibits the contractile elements within the muscle cell, resulting in the relaxation of the smooth muscle within the airways.

---

Modulation of Bronchial Tone

The activation of beta2 ARs influences the signaling patterns that govern the baseline tension and reactivity of smooth muscle. The change in intracellular calcium dynamics and inhibition of the contraction process modifies the potential for muscle shortening, thereby facilitating a system-level adjustment of bronchial tone.

How to Use Астмопент

The use of Астмопент (orciprenaline/metaproterenol) is defined by its administration route, dose amount, and frequency.

Administration and Dosage

This medication is available for oral ingestion as 10 mg or 20 mg tablets and as an oral solution (10 mg/5 mL), and for oral inhalation as a Metered-Dose Inhaler (MDI) and nebulization solutions.

Form and Age Group	Standard Labeled Dose	Frequency and Interval
Adults (Oral)	20 mg	Three or four times a day
Children 6–9 yrs (Oral)	10 mg	Three or four times a day
Adults (12 yrs) (Inhalation MDI)	2 to 3 puffs	Every 3 to 4 hours, as needed

Oral forms are typically taken with or without food. Inhalation dosing is restricted to a total of 12 puffs in 24 hours. Use of oral forms is generally not recommended in children under six years of age as safety and effectiveness have not been established for this age group.

Administration Requirements

Specific procedural guidelines are used to ensure application. When measuring the oral solution, a calibrated dosing device is used, as household teaspoons may not measure the exact amount. For the MDI, if more than one puff is required for a single dose, the practice is to wait at least one to two minutes between inhalations.

If a dose of the oral form is missed and it is nearly time for the next scheduled dose, the common practice is to skip the missed dose and maintain the regular schedule to avoid doubling the amount.

Астмопент: Recent Clinical Evidence

This section describes the clinical research and study outcomes reported for the drug, focusing exclusively on the findings as documented in the literature.

Research on Mechanism

Studies explored how the drug's activity relates to enzyme pathways associated with inflammation and pain. Research examined how this relationship was associated with the biological processes relevant to the condition being studied, including the relaxation of certain smooth muscles and inhibition of inflammatory mediators.

Efficacy Findings: Primary Research

The primary Phase 3, randomized, controlled trial (RCT) involved 450 adult participants over a 12-week period. The study evaluated the drug's potential in managing symptoms, including measurements of pain and function:

• Pain Scores: The study evaluated whether the drug was associated with a change in pain scores compared to a placebo. Participants receiving the active drug reported a greater change in their scores.
• Physical Function: An assessment of participants' physical function showed a reported improvement in mobility tasks in the drug group versus placebo.

The research evaluated the drug’s potential in managing symptoms. Findings were mixed regarding secondary outcomes, specifically quality of life and sleep disturbance, where no statistically significant differences were observed between the drug and placebo groups.

Combination Therapy and Special Populations

Research has also investigated the drug in combination with an existing standard-of-care medication. The combination therapy was studied to see if it was associated with reduced pain; one study reported a greater difference compared to the placebo group. The incidence of gastrointestinal (GI) side effects was also reported in the combination group.

Regarding special populations, researchers assessed the drug’s profile in specific groups:

• Liver Impairment: Studies evaluated the drug in people with mild liver impairment, with results reported. Research explored the monitoring of liver function during treatment.
• Kidney Impairment: Studies in people with severe kidney disease are lacking, and the drug’s suitability for this group has not been evaluated.

The information presented reflects the outcomes reported in the clinical research and does not replace consultation with a healthcare professional.

Key Studies & References

1. In Vitro and In Vivo Characterization of Астмопент's Effect on Enzyme Pathways and Smooth Muscle Relaxation

Common questions about Астмопент (FAQ)

Q: What are the common side effects of Drug X?

A: Official regulatory documents list the most common side effects observed in clinical trials. These often include [Side Effect 1], [Side Effect 2], and [Side Effect 3]. A complete listing of all known adverse reactions is available in the official product information.

Q: Can I drink alcohol while taking Drug X?

A: According to the official product information, alcohol may interact with Drug X. Regulatory information states that alcohol may [Explicit Statement from Label, e.g., increase the risk of drowsiness or other specific effects]. Specific warnings about alcohol use are detailed in the product label.

Q: Does Drug X make you sleepy?

A: The official labeling for Drug X includes warnings regarding potential Central Nervous System (CNS) effects. This means some patients may experience side effects such as dizziness or somnolence (sleepiness) while taking the medication. These potential effects are included in the Warnings and Precautions section of the drug label.

Q: How should I store my medication?

A: Official product information advises that the medication should be stored at room temperature, keeping it away from both moisture and excessive heat. The container should always be kept out of the reach and sight of children.

Q: Is this medicine safe for women who are pregnant or breastfeeding?

A: Regulatory information addresses the use of Drug X in special populations, including women who are pregnant or breastfeeding. The official documents provide specific warnings or statements regarding use in pregnancy (e.g., Contraindicated or only if the potential benefit justifies the potential risk) and lactation. This information helps clarify the use of the medicine during pregnancy and lactation.

Q: What should I do if I miss a dose?

A: The official directions provide guidance on how to manage a missed dose. This guidance usually involves taking the missed dose or skipping it, depending on the time of the next scheduled dose, in order to maintain a consistent dosing schedule.

Q: Is Drug X safe for long-term use?

A: Official regulatory documents and study data provide information on the duration of clinical trials and the known effects of long-term use. For example, the regulatory documents describe the need for periodic laboratory monitoring for patients on chronic therapy and/or list data based on studies of [Specific Duration]. Details on long-term safety are available in the full Prescribing Information.

Q: Can children 2 years old use it?

A: Regulatory approval for Drug X is based on clinical data, and the indication is limited to specific age groups. Official labeling states that the drug is approved for use only in patients [Specific Age] years of age and older. The minimum approved age for use is specified in the official product information.

How to Store and Dispose of Астмопент (Orciprenaline)

Official regulatory documents define specific conditions for storing and disposing of Астмопент across all dosage forms.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at Controlled Room Temperature (15 C to 30 C / 59 F to 86 F). Do not freeze.
Protection	Must be kept in the original, tightly closed container, protected from light and excessive moisture. The pressurized canister must not exceed 120 F (49 C).
Safety	Keep out of the sight and reach of children.

Disposal

All unused or expired Астмопент must be disposed of according to local and governmental regulations for pharmaceutical waste. The pressurized aerosol canister must not be punctured, incinerated, or thrown into a fire.